Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 46,150

Document Document Title
WO/2014/087367
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount ...  
WO/2014/087110
A method for the industrial synthesis of an addition salt with a pharmaceutically acceptable acid of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benz amide of formula (I), in which ΗΧ represents a pharmaceutically acceptabl...  
WO/2014/088326
The present invention relates to a composition and health functional food for inhibiting apoptosis of cranial nerve cells, and to a method for inhibiting apoptosis, wherein the composition and health functional food comprising a phosphod...  
WO/2014/089449
Provided herein are methods for treatment of a neurodegenerative disease, such as neuronal ceroid lipofuscinosis including administering to a subject in need of such treatment a composition comprising a therapeutically effective amount o...  
WO/2014/088106
A substance capable of binding to mSin3B, said substance exhibiting an analgesic effect on an ICS (intermittent cold stress) mouse, which is an experimental animal model of fibromyalgia, and, therefore, being useful as a prophylactic or ...  
WO/2014/088519
The present invention relates to certain piperazine-based compounds that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b and/or as ABL or ABL (T315I) inhibitors. The invention further relates to pha...  
WO/2014/086243
Disclosed are a miRNA molecule for negatively regulating a type I interferon pathway and uses thereof, discovering that Has-miR-127-3p is closely related to systemic lupus erythematosus, and also verifying the target pathway of the miRNA...  
WO/2014/085851
The present invention broadly relates to methods for acutely improving/enhancing cognitive performance in a human subject comprising administration of an extract of Bacopa monnieri.  
WO/2014/089149
This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid ...  
WO/2014/087298
The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or –CR0 --, where R0 is hydrogen, C1 -C6 linear or branched chain alkyl, etc., Z is –CRe --, or, –N--, where Re is hydrogen, C1 -C6 linear or branched...  
WO/2014/086258
The present invention discloses that Yam glycoprotein can improve the activity of the key enzyme of brain cell mitochondria for oxidative metabolism, i.e., pyruvate dehydrogenase and α-ketoglutarate dehydrogenase, and thus can be used f...  
WO/2014/085367
A method for treating a condition selected from Alzheimer's disease, mild cognitive impairment, age-associated dementia, and frontotemporal dementia, comprises administering to a patient in need of such treatment a safe and effective amo...  
WO/2014/084744
The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in w...  
WO/2014/083107
The present invention relates to a process of preparation of Crystal Forms of 4- (cyclopropylmethoxy)-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5- methoxypyridine-2- carboxamide of formula (I), said Crystal Forms which are designated as Cryst...  
WO/2014/084311
The purpose of the present invention is to provide an adhesive patch that is obtained by blending ropinirole, which is in a free form, in an adhesive base, said adhesive patch having good and lasting percutaneous absorption, excellent me...  
WO/2014/085600
A compound having formula I is useful for treating a neurodegenerative disease: I, R1 is an C1-12 organyl group; is a C1-12 heterocyclic ring system containing 5 to 12 ring atoms and up to three heteroatoms individually selected from the...  
WO/2014/082739
The invention relates to amino-arylcarboxamides of formula (I), to pharmaceutical compositions containing these compounds and also to these compounds for use In the treatment and/or prophylaxis of pain and further diseases and/or disorders.  
WO/2014/082737
The invention relates to specific carboxamides of formula (I) as KCNQ2/3 modulators, to processes for their preparation, to medicaments comprising these compounds and to the use of these compounds in the preparation of medicaments.  
WO/2014/083522
The present invention relates to trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]- ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine (cariprazine) and pharmaceutically acceptable salts and hydrates and solvates and polymorphs thereof for us...  
WO/2014/084401
[Problem] To provide a medical patch with an adhesive layer formed thereon, said medical patch containing a large amount of a drug and a dissolution auxiliary, being flexible without losing shape and leaving behind adhesive residue, and ...  
WO/2014/085153
A TARP γ8 dependant AMPA receptor antagonist of the formula: (I) its pharmaceutically acceptable salts, uses, and methods for its preparation are described.  
WO/2014/083003
The invention relates generally to a compound according to formula I - more in particular la or lb, a stereochemically isomeric form thereof, an N-oxide form thereof, or a pharmaceutically acceptable acid or base addition salt thereof-, ...  
WO/2014/083071
A liquid formulation for intravenous infusion comprising tramadol and paracetamol in a non-deoxygenated aqueous solvent. The formulation has shown to be suitable for intravenous infusion, is stable upon autoclaving with a minimum loss of...  
WO/2014/085362
Methods for the treatment of Parkinson's disease psychosis which comprise the administration of pimavanserin.  
WO/2014/084085
The present invention addresses the problem of providing an efficacious means for preventing or treating declines in neurophysiological functions controlling hearing ability, motions, etc. Provided is a prophylactic/therapeutic agent for...  
WO/2014/085153
A TARP γ8 dependant AMPA receptor antagonist of the formula: (I) its pharmaceutically acceptable salts, uses, and methods for its preparation are described.  
WO/2014/085284
Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, preventi...  
WO/2014/082548
Disclosed are a 2-aryl selenazole compound and pharmaceutical composition thereof, being a compound as represented by formula (I) or pharmaceutically acceptable salt thereof. The 2-aryl selenazole compound has xanthine oxidase inhibition...  
WO/2014/084616
The present invention provides a pharmaceutical composition containing a Sceptridium japonicum extract, as an active ingredient, for preventing or treating stroke or degenerative brain diseases. The Sceptridium japonicum extract of the p...  
WO/2014/083327
The invention provides a compound of formula (I), wherein R1, R2, R3, R4, R5, Ra and Rb have the meanings given in the description, with the proviso that the compound is not a compound selected from the group given in the description. Th...  
WO/2014/085668
The present invention relates to methods of preventing, inhibiting, delaying, and/or mitigating seizures by administration of a steroid, e.g., a neurosteroid, e.g., allopregnanolone.  
WO/2014/083068
The invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein R1 is C1-8 alkyl, C1-8 alkoxy, CN, NO2, amino, COOH, COOCH3, OH, N3, or halogen and R2 is H, OH, Cl-8 alkyl, Cl-8 alkoxy, C2-C6 al...  
WO/2014/084460
The present invention relates to a composition comprising an Acanthopanax koreanum extract as an active ingredient. More particularly, the present invention relates a pharmaceutical composition comprising the Acanthopanax koreanum extrac...  
WO/2014/082738
The invention relates to substituted heteroquinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or di...  
WO/2014/085413
Pharmaceutical compositions of the invention comprise disubstituted oxazolidin-2-ones derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 2b activity.  
WO/2014/082514
Provided in the present invention is a method for initiating the proliferation, migration and differentiation of stem cells in mammals, comprising the following steps: preparing a stem cell initiation agent containing chlorine dioxide an...  
WO/2014/080633
The present invention relates to novel crystal forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy }methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxy lic acid. More particularly, the invention relates to polym...  
WO/2014/080285
The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent  
WO/2014/081820
Novel CFTR corrector compounds that are effective in rescuing halide efflux, delF508-CFTR protein processing, and apical functional chloride ion transport in a cell are provided. Also provided are methods for treating protein folding dis...  
WO/2014/081029
The purpose of the present invention is to prevent, treat or alleviate peripheral nerve disorders caused by anti-cancer agents satisfactorily and sustainably. The present invention provides a prophylactic, therapeutic or alleviating agen...  
WO/2014/081025
This invention relates to an I-form crystal of the free form of 3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyetho xy)-5-(3-oxo-[1,2]-oxazinan-2-ylmethyl)benzamide, the crystal, in analysis by X-ray powder diffraction with CuK...  
WO/2014/080241
The invention provides compounds of formula (1), stereoisomers and tautomers thereof, or pharmaceutically acceptable salts, solvates and polymorphs thereof, and processes for their preparation. The invention further relates to pharmaceut...  
WO/2014/080973
Provided is an antidementia drug that has a high safety and is free of the problem of side effects. Also provided is a learning/memory function-improving drug that is useful in improving the learning/memory function and can be continuous...  
WO/2014/079504
The invention relates to a new class of compounds able to bind with high affinity and selectivity the 5-HT7 receptor. The invention also relates to the utilization of such compounds as medicaments useful in the treatment and prevention o...  
WO/2014/080063
The invention relates to a recombinant protein and to the uses thereof in the diagnosis and treatment of multiple sclerosis. The invention also relates to the recombinant protein IFNAR2.3, to antibodies, compositions comprising same, and...  
WO/2014/079995
The present invention relates to compounds of the formula I and their salts etc. which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controll...  
WO/2014/079787
The present invention relates to the use of compounds of general formula (I) wherein R' is hydrogen or lower alkyl; R1 is halogen, lower alkyl, cycloalkyl or cyano; or is phenyl, optionally substituted by one to three substituents, selec...  
WO/2014/080342
Our invention relates to trans-(4-{4-[2-(4-amino-cyclohexyl)-ethyl]-piperazin-1-yl}-5 ,6- dichloro-pyrimidin-2-yl)-methylamine dihydrochloride monohydrate, the process for the synthesis of this compound, the new (4,5-dichloro-6-piperazin...  
WO/2014/079964
A frozen confection comprising from 0.002 wt% to 1 wt% of one or more compounds selected from the group consisting of benzyl cinnamate, piperonal, 4-methoxybenzaldehyde, and 4-hydroxybenzaldehyde is provided. A product for use in improvi...  
WO/2014/080784
An aqueous pharmaceutical preparation characterized in containing olanzapine and water, the pH during preparation being 7 to 10.  

Matches 201 - 250 out of 46,150